{"nctId":"NCT01644331","briefTitle":"Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure","startDateStruct":{"date":"2012-10"},"conditions":["Heart Failure","Dyspnea"],"count":257,"armGroups":[{"label":"Tolvaptan","type":"EXPERIMENTAL","interventionNames":["Drug: Tolvaptan"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tolvaptan","otherNames":["Samsca"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* ≥ 18 years of age\n* Daily oral dose of furosemide between ≥ 40 mg(or equivalent)\n* Identified within 24 hours of presentation, defined for purposes of this study as the time of initial dose of intravenous loop diuretic\n* Prior clinical HF diagnosis that was treated with oral loop diuretics for at least 1 month\n* Admission for acute decompensated Heart Failure (HF) as determined by\n\n  * dyspnea at rest or with minimal exertion\n  * Brain Natriuretic Peptide (BNP) \\> 400 or NTproBNP \\> 2000 pg/mL\n\nAND at least one of the following additional signs and symptoms:\n\n* Orthopnea\n* Peripheral edema\n* Elevated JVP (Jugular Venous Pressure)\n* Pulmonary rales\n* Congestion on Chest X-ray\n* No plan for revascularization, cardiac transplant, of ventricular assist device implantation, or other cardiac surgery within 60 days of randomization\n* Signed informed consent\n\nExclusion Criteria:\n\n* Serum Na \\> 140 meq/L\n* Received IV vasoactive treatment or ultra-filtration therapy for HF since initial presentation\n* Treatment plan during current hospitalization includes IV vasoactive treatment or ultra-filtration for HF\n* Systolic Blood Pressure (SBP)\\<90mmHg\n* Serum-Cr\\>3.5mg/dl or currently undergoing renal replacement therapy\n\n  . Known underlying liver disease\n* Hemodynamically significant arrhythmias\n* ACS(Acute coronary syndrome) within 4 weeks prior to study entry\n* Active myocarditis\n* Hypertrophic obstructive, restrictive, constrictive cardiomyopathy\n* Severe stenotic valvular disease\n* Complex congenital heart disease\n* Constrictive pericarditis\n* Clinical evidence of digoxin toxicity\n* Need for mechanical hemodynamic support\n* Terminal illness (other than heart failure) with expected survival time of less than 1 year\n* History of adverse reaction to Tolvaptan\n* Enrollment or planned enrollment in another randomized clinical trial during this hospitalization\n* Pregnant or breast-feeding\n* Inability to comply with planned study procedures","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Dyspnea Improvement Measured by Likert Scale at 8 and 24 Hours","description":"The number of patients with at least moderate improvement (as reported by patient) in dyspnea Likert scale at both 8 AND 24 hours AND without the need for escalation of therapy due to worsening heart failure (rescue therapy) or death within 24 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Renal Function","description":"Change in Serum creatinine from baseline to 24, 48 and 72 hours","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.4"},{"groupId":"OG001","value":"0.04","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.4"},{"groupId":"OG001","value":"0.05","spread":"0.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.6"},{"groupId":"OG001","value":"0.06","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Weight Loss","description":"Change in body weight from baseline to 24, 48, and 72 hours","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.41","spread":"6.6"},{"groupId":"OG001","value":"-1.16","spread":"13.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.11","spread":"7.4"},{"groupId":"OG001","value":"-3.46","spread":"6.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.19","spread":"9.7"},{"groupId":"OG001","value":"-5.53","spread":"7.0"}]}]}]},{"type":"SECONDARY","title":"Fluid Loss","description":"Change from baseline fluid balance at 24, 48, and 72 hours","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2182.25","spread":"1844.4"},{"groupId":"OG001","value":"-1541.48","spread":"1524.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1948.01","spread":"1635.6"},{"groupId":"OG001","value":"-1419.09","spread":"1378.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1757.09","spread":"1670.4"},{"groupId":"OG001","value":"-1401.24","spread":"1386.5"}]}]}]},{"type":"SECONDARY","title":"Dyspnea Likert","description":"Number of patients that experience moderate or greater improvement (patient reported) in dyspnea by 7 point Likert scale at 48 and 72 hours","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]},{"type":"SECONDARY","title":"Hospital Stay","description":"Total days spent in hospital from baseline until discharge or death","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.46","spread":"5.9"},{"groupId":"OG001","value":"7.35","spread":"7.0"}]}]}]},{"type":"SECONDARY","title":"Worsening or Persistent Heart Failure or Death","description":"Number of patients with worsening heart failure or death","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Over-diuresis","description":"clinical evidence of volume depletion requiring intervention other than holding diuretics during the 72 hours after randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Sodium","description":"Change in serum sodium from baseline to 24, 48, and 72 hours","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.18","spread":"3.3"},{"groupId":"OG001","value":"0.23","spread":"2.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.34","spread":"3.7"},{"groupId":"OG001","value":"-0.24","spread":"2.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.84","spread":"3.9"},{"groupId":"OG001","value":"-0.44","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"Dyspnea 11 Point NRS","description":"Change in NRS for assessment of dyspnea from baseline to 24, 48, and 72 hours (scale ranges from 0-No difficulty breathing to 10-Difficulty as bad as you can imagine)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.20","spread":"2.5"},{"groupId":"OG001","value":"-1.84","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.85","spread":"2.7"},{"groupId":"OG001","value":"-2.29","spread":"2.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.07","spread":"3.0"},{"groupId":"OG001","value":"-2.42","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Freedom From Congestion","description":"Jugular Venous Pressure (JVP) \\< 8 cm, no orthopnea, trace peripheral edema or less, and will be assessed at 24, 48, and 72 hours","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Development of Worsening Renal Function","description":"increase in serum creatinine ≥ 0.3mg/dl from randomization at any time point during 72 hours after randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"Days Hospitalized or Deceased","description":"Total days hospitalized or deceased during the 30 days after randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.19","spread":"10.9"},{"groupId":"OG001","value":"11.69","spread":"11.7"}]}]}]},{"type":"SECONDARY","title":"All Cause Death or Rehospitalization","description":"All cause death or rehospitalization (to include unscheduled clinic visits or ED visits) at 30 days (Kaplan-Meier and 95% confidence interval)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":null},{"groupId":"OG001","value":"0.29","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":129},"commonTop":["Worsening Heart Failure","Acute Renal Failure","Atrial Fibrillation","Death","Ventricular Tachycardia"]}}}